Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Govoni

Showing results (11-20 of 16) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 16 results.
Science Translational Medicine|September 8, 2017
New class of precision antimicrobials redefines role of <i>Clostridium difficile</i> S-layer in virulence and viabilityJoseph A Kirk, Dana Gebhart, Anthony M Buckley, et al.
Mbio|March 26, 2015
A modified R-type bacteriocin specifically targeting Clostridium difficile prevents colonization of mice without affecting gut microbiota diversityDana Gebhart, Stephen Lok, Simon Clare, et al.
Journal of Pediatric Endocrinology & Metabolism : JPEM|March 26, 1999
Growth hormone secretion and bone histomorphometric study in thalassaemic patients with acquired skeletal dysplasia secondary to desferrioxamineV De Sanctis, S Stea, L Savarino, et al.
Journal of Bacteriology|September 18, 2012
Novel high-molecular-weight, R-type bacteriocins of Clostridium difficileDana Gebhart, Steven R Williams, Kimberly A Bishop-Lilly, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 6, 2010
Two physically, functionally, and developmentally distinct peritoneal macrophage subsetsEliver Eid Bou Ghosn, Alexandra A Cassado, Gregory R Govoni, et al.
Plos Pathogens|December 4, 2009
The Salmonella SPI2 effector SseI mediates long-term systemic infection by modulating host cell migrationLaura M McLaughlin, Gregory R Govoni, Christiane Gerke, et al.
Pageof 2

Showing results (11-20 of 16) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
Science Translational Medicine|September 8, 2017
New class of precision antimicrobials redefines role of <i>Clostridium difficile</i> S-layer in virulence and viabilityJoseph A Kirk, Dana Gebhart, Anthony M Buckley, et al.
Mbio|March 26, 2015
A modified R-type bacteriocin specifically targeting Clostridium difficile prevents colonization of mice without affecting gut microbiota diversityDana Gebhart, Stephen Lok, Simon Clare, et al.
Journal of Pediatric Endocrinology & Metabolism : JPEM|March 26, 1999
Growth hormone secretion and bone histomorphometric study in thalassaemic patients with acquired skeletal dysplasia secondary to desferrioxamineV De Sanctis, S Stea, L Savarino, et al.
Journal of Bacteriology|September 18, 2012
Novel high-molecular-weight, R-type bacteriocins of Clostridium difficileDana Gebhart, Steven R Williams, Kimberly A Bishop-Lilly, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 6, 2010
Two physically, functionally, and developmentally distinct peritoneal macrophage subsetsEliver Eid Bou Ghosn, Alexandra A Cassado, Gregory R Govoni, et al.
Plos Pathogens|December 4, 2009
The Salmonella SPI2 effector SseI mediates long-term systemic infection by modulating host cell migrationLaura M McLaughlin, Gregory R Govoni, Christiane Gerke, et al.
Pageof 2